2018
DOI: 10.1016/j.rx.2018.02.005
|View full text |Cite
|
Sign up to set email alerts
|

Cómo integrar la información cuantitativa en el informe radiológico del paciente oncológico

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(7 citation statements)
references
References 19 publications
0
6
0
1
Order By: Relevance
“…Nevertheless, most results emerging from radiomic studies are negatively affected by a reduced number of cases collected, and novel biomarkers need to be validated in large multicentre populations. A small sample size can be a critical shortcoming for finding statistically significant correlations between treatment outcomes and radiomics features with high confidence intervals [80,81]. This problem is especially significant when the different data repositories that form biobanks are intended to be used as a basis for the generation of predictive models (i.e.…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, most results emerging from radiomic studies are negatively affected by a reduced number of cases collected, and novel biomarkers need to be validated in large multicentre populations. A small sample size can be a critical shortcoming for finding statistically significant correlations between treatment outcomes and radiomics features with high confidence intervals [80,81]. This problem is especially significant when the different data repositories that form biobanks are intended to be used as a basis for the generation of predictive models (i.e.…”
Section: Discussionmentioning
confidence: 99%
“…Oncologic imaging represents a suitable field for the discovery and validation of new biomarkers from different imaging modalities (such as computed tomography, magnetic resonance, positron emission tomography, and ultrasound), since cancer patients are frequently monitored for staging and treatment response follow-up [7]. Many imaging biomarkers have been proposed over the last years to measure tumour anatomy, morphology, pathophysiology, metabolism, or molecular profiles in order to estimate different cancer hallmarks, such as proliferation/ growth, angiogenesis, and evasion or metastasis [8].…”
Section: Imaging Biobanks and In Silico Modelsmentioning
confidence: 99%
“…This project will bring major advancements in the validation of novel imaging biomarkers; it will create advanced computational models for tumour growth simulation, given response to specific CEPs. A very limited number of imaging biomarkers have been used in routine clinical practice to guide clinical decisions [7][8][9]. Therefore, PRIMAGE predictive models will enable unprecedented effectiveness in the translation from clinical Big Data to personalised predictors for malignant solid tumours, particularly NB and DIPG, by incorporating these assets for Big Data to usable clinical knowledge translation.…”
Section: Clinical Datamentioning
confidence: 99%
“…Imaging biobanks store image collections, just as standard biobanks store biological samples, and donors of images can be described in the same way as donors of samples. Most imaging biobanks focus on the collection of cancer-related data and oncologic imaging biomarkers [ 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%